Market Research Report
Global Central Nervous System (CNS) Biomarkers Market - 2021-2028
|Global Central Nervous System (CNS) Biomarkers Market - 2021-2028|
Published: December 1, 2021
Content info: 180 Pages
Delivery time: 2 business days
Biomarkers are measurable biological indicators that help understand the development of chronic diseases, their relationship with environmental chemicals and identify subjects at high risk of developing the disease.
The global central nervous system (CNS) biomarkers market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
The development of novel biomarkers for diagnosing and treating Alzheimer's disease is expected to drive market growth.
Increased life expectancy has resulted in an older population, which has increased dementia prevalence. Alzheimer's disease (AD) is the most common form of dementia, accounting for 50-80 percent of cases globally. By 2050, there are estimated to be 131 million cases of Alzheimer's disease. There is presently no medication that can slow or stop the progression of the disease. Moreover, the late diagnosis of Alzheimer's disease is a significant impediment to effective disease management. However, some well-known and recently discovered AD biomarkers could be used to detect the illness early on and track its course. Because of their efficacy as diagnostic tools, proteins like NfL, MMPs, p-tau217, YKL-40, SNAP-25, VCAM-1, and Ng/BACE are among the most promising biomarkers. For instance, Recent research has revealed the predictive utility of plasma p-tau217 in distinguishing Alzheimer's disease from other neurodegenerative illnesses, particularly as an accurate predictor of -amyloidosis at both the asymptomatic and symptomatic stages.
With the high cost of the validation process, such as sample collection & storage, government rules and policies are changing since reimbursements do not cover biomarker-mediated therapies that are not considered standard of care. Even though biomarkers add significant value to tests, reimbursements are limited. For instance, Medicare, the nation's largest healthcare insurer with more than 50 million beneficiaries, does not fund experimental medicines or most screening and biomarker tests. Therefore, above are some of the factors that the market is expected to hamper in the forecast period.
Patients with COVID-19 typically report suffering neurological symptoms. Anosmia is a common CNS symptom induced by viral contact with neurons or supporting cells in the nasal olfactory tissues. The most common symptom of CNS dysfunction is diffuse encephalopathy, which is most likely caused by the CNS consequences of the systemic inflammatory state associated with severe COVID-19. Moreover, CSF and plasma biomarkers will very certainly play a vital role in the clinical evaluation of patients with neuro-COVID, both during the acute phase of infection and for managing long-term complications. Unnecessary deaths.
Also, in the early stages of the pandemic, the rate of patient screening and diagnosis is greatly hampered since governments worldwide instituted restrictions such as lockdowns to stop the disease from spreading. Screening, diagnosis and treatment delays would probably result in a short-term decrease in CNS diagnoses, followed by an increase in late-stage diagnoses and deaths due to limited healthcare coverage. As a result of the expanding number of COVID-19 cases, there is more evidence of CNS injury in COVID-19 patients utilizing serological biomarkers.
Safety Biomarker segment is expected to hold the largest market share in central nervous system (CNS) biomarkers market.
The safety biomarker segment accounted for the largest market share in 2020. Growing awareness about routine health checkups and rising use in the preclinical stage are some of the factors the segment is expected to boost in the forecast period. For instance, according to a report published by a coalition of pharmaceutical companies in December 2020, 83 percent of the 24 companies surveyed used safety biomarkers throughout the clinical trials phase. In addition, great effort is being made to qualify biomarkers to be employed in preclinical and clinical trials to speed up medication development.
North America region holds the largest market share in the global central nervous system (CNS) biomarkers market
In 2020, North America accounted for the highest revenue share. The rising CNS cancer cases and increasing R&D expenditure are some of the factors which are expected to boost the market in the forecast period. For instance, According to the American Cancer Society, brain cancer will be the second most commonly diagnosed cancer in children and adolescents in 2021, with a proportion of 27 percent and 21 percent in children and adolescents, respectively, where CNS biomarkers are used.
Furthermore, businesses and research institutes continually innovate and develop new technologies and biomarkers, which significant players aid in the region. As per the American Cancer Society, as of August 2020, USD 23.1 million has been allocated to brain-related clinical and cancer control research in the United States. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Major key players in the central nervous system (CNS) biomarkers market are Banyan Biomarkers Inc., Thermo Fisher Scientific Inc., Merck KGaA(Sigma Aldrich), G-Biosciences, Zeus Scientific , Roche, Abacus Diagnostica and SGS OFFICES & LABS. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which contribute to the global growth of the central nervous system (CNS) biomarkers market. For instance, Accure Therapeutics announced its launch in June 2020, with EUR 7.6 million in Series A investment. The pharmaceutical business established in Barcelona will focus on discovering therapy candidates for CNS illnesses such as Parkinson's disease.
Banyan Biomarkers, Inc., headquartered in Gainesville, Florida, was founded in 2002. The company's biomarkers aim to eliminate the need for CT scans in patients with a suspected mild traumatic brain injury based on actual data rather than subjective interpretation, allowing physicians to identify and triage patients who require additional medical attention while also reducing unnecessary CT scan radiation exposure.
BANYAN BTI: The BANYAN BTI measures the levels of two proteins, Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP), released from the brain into the circulation and assessed within 12 hours of a head injury.
The global central nervous system (CNS) biomarkers market report would provide an access to an approx.45+ market data table, 40+ figures and 180 pages.
Global Central Nervous System (CNS) Biomarkers Market - By Type
Global Central Nervous System (CNS) Biomarkers Market - By Application
Global Central Nervous System (CNS) Biomarkers Market - By Disease
Global Central Nervous System (CNS) Biomarkers Market - By End user
Global Central Nervous System (CNS) Biomarkers Market - By Region
LIST NOT EXHAUSTIVE